Drug Profile


Alternative Names: AL-15469A/AL-38905; AL-15469A/AL-38905 ophthalmic formulation - Alcon Research; MoxiDex Otic; VIGADEXA

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alcon
  • Class Anti-inflammatories; Aza compounds; Fluorinated steroids; Pregnadienetriols; Quinolines
  • Mechanism of Action DNA gyrase inhibitors; Glucocorticoid receptor agonists; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation; Ophthalmic infections
  • Discontinued Corneal disorders; Otitis externa; Otitis media

Most Recent Events

  • 24 Mar 2014 Alcon withdraws a phase III trial for Ocular inflammation and infection (prevention) in Brazil prior to enrolment (NCT01515826) (Ophthalmic, gel)
  • 17 Feb 2014 Discontinued - Phase-II for Corneal disorders in USA (Ophthalmic)
  • 01 Jun 2013 Alcon plans a phase III trial for Ocular inflammation and infection (prevention) in Brazil (NCT01515826) (Ophthalmic, gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top